Short answer: No Dutch law bans research peptides as substances. The Geneesmiddelenwet regulates medicines: anything presented as suitable for treating people, or intended to be given to people to modify physiological functions, needs a marketing authorisation, and selling, importing or stocking it without one is an economic offence. A vial sold strictly as a laboratory reagent sits outside that regime; a vial presented for human use, with health claims or instructions for use in people, does not. In 2026 the IGJ said "research purposes" wording protects no seller and ordered a Dutch web shop to stop selling unlicensed medicines. Public sources report enforcement against sellers and parcels, not individual buyers.
Disclosure: Peps and Protocols is published by the team behind Vitality Peps. Vendor facts below were checked on each vendor's public website on the date shown, and the criteria are the same for every vendor. This article is general information, not legal advice; rules change and enforcement varies, so check the current position with a qualified adviser in your country.
The Netherlands has no peptide-specific law. The dividing line is the definition of a medicine in article 1 of the Geneesmiddelenwet, copied from Directive 2001/83/EC: a substance is a medicine if it is presented as suitable for treating disease in humans, or intended to be administered to humans to modify physiological functions. A research peptide falls on either side depending on how it is sold.
Neither test turns on the label alone. Announcing 43 website takedowns in April 2026, the IGJ and NVWA wrote that sellers try to circumvent the law with phrases such as "voor onderzoeksdoeleinden" while supplying anyone who orders; the Douane added on 6 August 2026 that research purposes "play no role" once a substance falls under the law. A reagent sold to laboratories without health claims is a chemical; a vial presented for human use, with health claims or instructions for use in people, is, in the regulators' reading, an unlicensed medicine.
The Geneesmiddelenwet contains no stand-alone offence of possessing a medicine for personal use. Its prohibitions target the supply chain: article 18 requires a licence to manufacture, import, stock, offer or deliver medicines, and article 40 bans stocking, selling, delivering or importing a medicine that has no marketing authorisation. Both are economic offences under the Wet op de economische delicten.
That Act lists articles 18(1) and 40(1) and (2); an intentional breach is a misdrijf with a maximum of six years' imprisonment. The wording of article 40(2), "in voorraad te hebben", is not limited to traders; we found no published case applying it to a private buyer with a few vials, which is an observation about enforcement, not an exemption. The only personal-use carve-out, article 18(6)(a), covers medicines a traveller carries, not post.
In 2026 the regulator moved from warnings to orders. On 13 February 2026 an IGJ spokesperson told BNR that offering medicines without a marketing authorisation is illegal "even with terms such as for research purposes". On 18 August 2026 the IGJ issued a formal order (bevel) to the web shop Peptidekoning, adding on 31 August a penalty of 10,000 euro per day, capped at 200,000 euro.
According to the IGJ notice, the shop sold products containing three active substances that are prescription-only or still experimental medicines, marketed as slimming products, without the required licences; the inspectorate cited reports of harm and falsified versions. We do not name the substances because this publication does not cover them. Earlier, on 30 March 2026, Pointer Checkt had the LUMC test five products from five Dutch web shops: all five contained more active substance than labelled, up to fourteen times as much.
Yes, and the mechanism is predictable. A parcel from outside the EU, including the United Kingdom since Brexit, is cleared through Dutch customs. The Douane's handbook states that importing medicines by post or courier requires a manufacturer's licence under article 18 of the Geneesmiddelenwet; the traveller exemption does not apply to mail. Since 1 July 2026 no duty exemption applies below 150 euro.
The carrier holds the parcel and files the declaration; 21 per cent VAT, a flat 3 euro duty per product category and a clearance fee are charged. The Douane's post and parcel unit scans incoming mail around the clock, lists "illegal medicines (Geneesmiddelenwet)" among its priorities, and states that illegal medicines are seized and destroyed.
A parcel from another EU member state is not an import in customs terms, nor "invoer" under the Geneesmiddelenwet, which defines import as bringing goods in from a third country. There is no declaration, duty or clearance step. The Douane still checks international post "both within the EU and outside it", and article 40(2) covers bringing an unlicensed medicine in by any means, so intra-EU is lower friction, not a legal void.
The risk shifts from the border to the product page: a reagent moves freely, while a product presented for human use is not cured by the intra-EU route. EU stock also keeps a vial out of a clearance warehouse; Vitality Peps dispatches from Spain and the Netherlands within 24 hours, with delivery in 1 to 3 business days, per its shipping page.
Research use only (RUO) means the supplier sells the vial as a laboratory reagent for in vitro work, makes no health claims and does not supply it for administration to people. No Dutch licence is needed to buy a reagent, and no licence would make a product presented for human use a lawful medicine. RUO describes presentation and purpose, not permission.
The exemption for "geneesmiddelen voor onderzoek" in article 40(3)(b) covers investigational medicinal products in clinical trials under Regulation 536/2014, not RUO chemicals sold online. A buyer who uses an RUO product on themselves has stepped outside what was sold; regulators judge context, not stickers.
Four checks separate a research supplier from a grey shop: a batch-specific certificate of analysis from a named independent laboratory, stock physically inside the EU, payment through regulated rails such as iDEAL or card, and a product page without health claims or dosing instructions. The Pointer test showed why the first check matters.
A certificate should carry your vial's batch number and the laboratory's name, as the guide to reading a peptide COA explains. Vitality Peps publishes Janoshik Analytical reports per batch on its lab results page; checked on 3 September 2026, its how-to-order page lists card, Apple Pay, Google Pay and crypto. A fuller checklist is in where to buy research peptides in Europe.
| Scenario | What the law says | Source |
|---|---|---|
| Reagent from an EU supplier, no health claims, no instructions for human use | Not a medicine by presentation; free movement, no customs step | Geneesmiddelenwet art. 1(1)(b); Directive 2001/83/EC art. 1(2) |
| Web shop presents the vial for human use (health claims, instructions for use in people) | Unlicensed medicine; seller breaches art. 40; IGJ orders and penalties | IGJ bevel, 18 August 2026 |
| Medicines by post from outside the EU | Import needs a manufacturer's licence; traveller exemption excludes mail; parcel destroyed | Douane handbook VGEM; Geneesmiddelenwet art. 18 |
| A few vials held at home | No specific possession offence; art. 40(2) broadly worded; no published enforcement against private buyers found | Geneesmiddelenwet art. 40(2); WED art. 1, 6 |
Buying a peptide sold as a laboratory reagent is not an offence in the Netherlands and needs no licence. Buying a product presented for human use means buying an unlicensed medicine; the seller is the Geneesmiddelenwet's primary target, but the buyer has no statutory exemption. Published enforcement targets sellers and parcels.
Public sources do not report police raids or prosecutions of private individuals for ordering a few vials. Published enforcement in 2025 and 2026 takes three shapes: orders against sellers, websites taken offline, and parcels seized at the border. Large orders look like trade and change that picture.
No. Neither compound holds a marketing authorisation in the Netherlands or elsewhere in the EU, and no research supplier may claim otherwise. Research use only means the product is not sold for human use at all, so "safe for human use" is not a question a supplier can answer; published research comes from cell and rodent models.
Under the Douane's guidance the parcel sits with the carrier, which may ask for information before filing a declaration. If the contents are medicines, providing details does not make the import lawful, because mail imports need a licence. If a letter follows, ask a lawyer before answering.
Expect card and, from Dutch shops, iDEAL; both run through a licensed payment provider that vets the merchant and preserves chargeback rights. Checked on 3 September 2026, Vitality Peps lists card, Apple Pay, Google Pay and crypto. A crypto-only shop has usually been refused by payment providers, a warning sign.